Elamipretide has been studied in mitochondrial disease and is the ingredient in a US-authorized medicine for a specific Barth syndrome indication. This profile distinguishes the labelled product, study findings and evidence limits.
SLU-PP-332 is a small-molecule research compound studied for estrogen-related receptor activity. The reviewed findings come from cells and animals. This profile distinguishes the labelled product, study findings and evidence limits.
The selected research on GHRH-(1–29) measures hormonal responses. Increased hormone concentrations are not the same as demonstrated functional or longevity benefits. This profile distinguishes the labelled product, study findings and evidence limits.
Semaglutide is used in authorized medicines. A product’s indication, formulation and manufacturer instructions determine which evidence applies. This profile distinguishes the labelled product, study findings and evidence limits.
Thymosin alpha-1 studies address specific clinical settings. A recent large sepsis trial is essential context for claims about immune benefits. This profile distinguishes the labelled product, study findings and evidence limits.
Tirzepatide has authorized manufactured products with specific indications and safety information. Clinical information should always name the product being discussed. This profile distinguishes the labelled product, study findings and evidence limits.
The selected source examines the KE sequence alongside other short peptides in aging fibroblast cultures. This profile distinguishes the labelled product, study findings and evidence limits.
Bremelanotide has an authorized US formulation for a defined sexual-desire disorder. That label should not be treated as approval of every PT-141 product. This profile distinguishes the labelled product, study findings and evidence limits.
The selected Prostamax research uses an induced prostate-hyperplasia model in rats. This is an experimental tissue outcome, not established human treatment. This profile distinguishes the labelled product, study findings and evidence limits.
PE-22-28 is studied as a shortened spadin-related peptide affecting TREK-1. The reviewed outcomes are from laboratory and animal models. This profile distinguishes the labelled product, study findings and evidence limits.